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Abstract
Development of the pulmonary circulation is a complex process with a spatial pattern that is tightly controlled. This process is
vulnerable for disruption by various events in the prenatal and early postnatal periods. Disruption of normal pulmonary vascular
development leads to abnormal structure and function of the lung vasculature, causing neonatal pulmonary vascular diseases.
Premature babies are especially at risk of the development of these diseases, including persistent pulmonary hypertension and
bronchopulmonary dysplasia. Reactive oxygen species play a key role in the pathogenesis of neonatal pulmonary vascular diseases
and can be caused by hyperoxia, mechanical ventilation, hypoxia, and inflammation. Besides the well-established short-term con-
sequences, exposure of the developing lung to injurious stimuli in the perinatal period, including oxidative stress, may also
contribute to the development of pulmonary vascular diseases later in life, through so-called ‘‘fetal or perinatal programming.’’
Because of these long-term consequences, it is important to develop a follow-up program tailored to adolescent survivors of
neonatal pulmonary vascular diseases, aimed at early detection of adult pulmonary vascular diseases, and thereby opening the
possibility of early intervention and interfering with disease progression. This review focuses on pathophysiologic events in the
perinatal period that have been shown to disrupt human normal pulmonary vascular development, leading to neonatal pulmonary
vascular diseases that can extend even into adulthood. This knowledge may be particularly important for ex-premature adults who
are at risk of the long-term consequences of pulmonary vascular diseases, thereby contributing disproportionately to the burden of
adult cardiovascular disease in the future.
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The development of the pulmonary vasculature is a highly
complex process, in which temporal and spatial expression
of multiple morphogens, transcription factors, and growth
factors regulates the diﬀerent stages of development.1–3 This
complex process of normal lung development, with its tight
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regulation of the expression of numerous regulators, can be
disrupted at multiple levels and in various stages of devel-
opment. Such disruption of normal development of the pul-
monary vasculature plays a pivotal role in the pathogenesis
of several neonatal pulmonary vascular diseases, including
persistent pulmonary hypertension of the newborn (PPHN)
and bronchopulmonary dysplasia (BPD). Understanding
the response of the developing lung to injury, and its
repair mechanisms, is of great importance for elucidating
pathogenic processes.
The development of the lung starts with the appearance
of a primitive lung bud, which splits to form the left and
the right lung. In the human embryo, at day 34 of gesta-
tion, each lung bud is already supplied by a pulmonary
artery extending from the outﬂow tract of the heart,
which is connected to a primary capillary plexus and
traced back via a vein to the prospective left atrium.2,4,5
Lung development continues in ﬁve diﬀerent stages
(embryonic, pseudoglandular, canalicular, saccular, and
alveolar). The alveolar stage, when the gas-exchanging
surface area develops, starts at week 36 of gestation and
continues after birth, even up to the third year of life
(Fig. 1).2,5,6
The development of the pulmonary vasculature is closely
related to that of the airways, as they develop at the same
time and follow the same spatial pattern (Fig. 1). Growing
evidence exists that tissue interactions of lung mesenchyme,
epithelium, and endothelium are critical for both branching
of the airways and growth and diﬀerentiation of the pul-
monary vasculature.4,5,7,8
The formation of the pulmonary vasculature is governed
by two principal mechanisms: vasculogenesis and angiogen-
esis. Vasculogenesis is the process by which angioblasts or
endothelial progenitor cells diﬀerentiate to vascular endo-
thelial cells and form blood vessels de novo. In angiogenesis,
new blood vessels arise by direct extension of pre-existing
vessels.8–10 The relative contribution of vasculogenesis and
angiogenesis to vessel formation in the developing lung is
still incompletely understood, but three hypotheses have
been forwarded.10 One hypothesis is that the proximal vas-
culature develops through angiogenesis, while the distal ves-
sels are formed by vasculogenesis. In the pseudoglandular
phase, these two structures then fuse through a lytic pro-
cess.11 The second hypothesis proposes that new arteries are
derived from a continuous expansion and coalescence of the
primary capillary plexus around the terminal airways, and
thus principally from vasculogenesis.4 The third hypothesis
proposes that lung vascular development occurs through
distal angiogenesis, through the formation of new capillaries
from pre-existing vessels at the periphery of the lung as the
lung bud grows.12
Pulmonary vascular development is regulated by inter-
play between many diﬀerent factors. Although a lot of
knowledge about the pulmonary vasculature development
is obtained through experiments in rodents, we will focus
on vascular endothelial growth factor (VEGF) and trans-
forming growth factor-beta (TGF-b), because their roles
have also been conﬁrmed in human samples. Among all
diﬀerent regulators of lung vascular development, VEGF
is a frequently studied and crucial regulator of normal
Fig. 1 Diagram illustrating normal lung development: airway structure and pulmonary vasculature.
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pulmonary vascular development. VEGF induces angiogen-
esis and is a key player in the regulation of vasculogenesis.13
VEGF exerts its eﬀect by binding to two trans-membrane
tyrosine-kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2
(Flk-1), which are strongly expressed in endothelial cells. In
addition to its mandatory role in the development of the
pulmonary vasculature, VEGF also plays an important
role in epithelial branching morphogenesis and alveolar
development.14,15 VEGF expression is regulated by
hypoxia-inducible factors (HIF)-1 and 2, which are tran-
scriptional complexes responding to changes in oxygen
levels. Normal lung development takes place in the relatively
hypoxic environment of the uterus. This ‘‘Everest in utero’’
stabilizes the HIF complex, leading to transcription of hyp-
oxic responsive target genes, such as VEGF, thereby stimu-
lating epithelial branching and vascular development.16–18
Another important growth factor in normal pulmonary
vascular development is transforming growth factor-beta
(TGF-b). The exact role of TGF-b signaling in lung devel-
opment is not known yet. However, it appears to play a key
role in epithelial–mesenchymal interactions as well as endo-
thelial–mesenchymal interactions. Thus, tightly regulated
temporal and spatial TGF-b signaling is necessary for
both normal branching morphogenesis and pulmonary vas-
cular development.19–21 A role for TGF-b signaling in pul-
monary vascular development is further underlined by the
observation that mutations in the bone-morphogenetic pro-
tein receptor II (BMP-RII), which lead to a disturbed bal-
ance between TGF-b -and BMP-signaling, as well as in
endoglin, a co-receptor of the TGF-b receptors, are asso-
ciated with pulmonary arterial hypertension.22,23
In this review, we will focus on several pathophysiologic
insults in the prenatal and early postnatal periods, which
can disrupt normal pulmonary vascular development and,
consequently, lead to a variety of neonatal pulmonary
vascular diseases that can extend even into adulthood
(Fig. 2). Most of these insults cause oxidative injury of the
pulmonary vasculature, which will therefore be discussed in
more detail. Babies that are born prematurely are particu-
larly vulnerable to disruptions in the pulmonary vascular
development. As improved neonatal care has dramatically
improved the survival of these babies, there is a growing
cohort of young adults that were born preterm.
Knowledge about pathophysiological processes in the
developing lung may be particularly important for these
ex-premature adults who are at higher risk for the long-
term consequences of pulmonary vascular diseases, thereby
contributing disproportionately to the future burden of
adult cardiovascular disease.24,25
Oxidative injury in early life
Reactive oxygen species (ROS) are oxygen-derived metab-
olites and can be subdivided into free radicals and oxidants.
Examples of free radicals, deﬁned as atoms or molecules
that contain unpaired electrons, are superoxide, nitric
oxide, and hydroxyl- and peroxyl-radical. Oxidants, such
as hydrogen peroxide, peroxynitrite, and lipid peroxide, do
not contain an unpaired electron and are therefore not free
radicals, but are highly reactive oxygenated molecules that
can easily lead to free radical reactions.26–30 Because of their
highly reactive nature, ROS can react with various intracel-
lular proteins and alter their structure and function.
Small amounts of ROS are continuously produced in the
human body, mainly during ATP production in the mito-
chondria, and have been shown to play a role in many sig-
naling processes.29–34 However, in order to prevent
deleterious eﬀects of ROS and to maintain proper cellular
function, the amount of ROS needs to be carefully con-
trolled. Protection of the cells against oxidative damage is
Fig. 2 Schematic illustrating perinatal adverse stimuli contributing to pulmonary vascular disease that can extend even into adulthood.
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ensured by cellular antioxidants, which include endogenous
antioxidants such as superoxide dismutase, catalase, gluta-
thione peroxidase, and several metal-binding proteins
(transferrin, ferritin, and albumin). Furthermore, there are
exogenous antioxidants present in food or dietary supple-
ments like vitamins C and E.29–34
Oxidative stress occurs when antioxidant defense mech-
anisms are insuﬃcient to cope with ROS production, either
through increased production of ROS or through insuﬃ-
cient presence of antioxidants. Oxidative stress causes de-
gradation of lipids, protein damage, and even DNA
damage.27,28,30,35–38 At birth, all newborns are exposed to
a sudden increase in oxygen tension compared to the hyp-
oxic environment in utero, leading to increased ROS pro-
duction. Also, several perinatal adverse events induce a high
exposure to ROS, as described below in more detail.
Neonates, and especially those who are born premature,
are particularly vulnerable to oxygen toxicity, as their
levels of antioxidant enzymes are inadequate and unable
to protect the rapidly growing tissues, including the develop-
ing lung, from oxidative injury.28,29,38–40 The endothelial
cells and the alveolar type II cells especially are extremely
susceptible to oxidative injury. Activation of transcription
factors and pathways by oxidative stress lead to inactivation
of surfactant, cellular dysfunction, and impaired cell sur-
vival.3,39–42 Thus oxidative injury plays a critical role in
the pathogenesis and pathophysiology of neonatal pulmo-
nary vascular disease such as BPD.43,44
Prenatal adverse stimuli
Placental hypoxia
Normal perfusion and function of the placenta is essential
for the fetus, as the placenta is ultimately responsible for
oxygen and nutrient supply to the fetus. A reduction in
the placental perfusion, and consequently placental hypoxia,
is associated with pre-eclampsia and intrauterine growth
retardation (IUGR).45,46
Pre-eclampsia is the most common maternal complica-
tion of pregnancy, characterized by hypertension, edema,
and proteinuria. It is a frequent cause of IUGR and prema-
ture birth, which are both risk factors for neonatal pulmon-
ary vascular diseases.47,48 Central to the pathogenesis of
pre-eclampsia is placental hypoperfusion and/or inﬂamma-
tion, resulting in oxidative stress and the release of vaso-
active factors by the diseased and hypoxic placenta.
It has been shown that ROS are elevated and antioxidant
levels are decreased in the maternal circulation in pre-
eclampsia.27,49–51 Studies on the oxidative stress in infants
born to mothers with pre-eclampsia have reported conﬂict-
ing outcomes. Some papers show an increased antioxidant
status, probably protecting the fetus against the maternal
oxidative stress.52–54 Others report elevated levels of ROS
and decreased levels of antioxidants in neonates of pre-
eclamptic mothers, contributing to ‘‘oxygen radical disease
of neonatology,’’ including BPD.42,55,56 The increased
maternal oxidative stress and ensuing endothelial dysfunc-
tion are thought to aggravate to placental hypoperfusion
and impact on the release of vasoactive factors by the dis-
eased and hypoxic placenta.57,58
Placental hypoxia induces an imbalance between pro-
angiogenic and anti-angiogenic factors. Thus, there is an
increased placental production of soluble fms-like tyrosine
kinase-1 (sFlt-1 or soluble VEGF-receptor 1) and soluble
endoglin (sEng).46,59,60 Elevated levels of sFlt-1 scavenge
free VEGF, thereby inhibiting VEGF signaling.46,59–62
Similarly, elevated levels of sEng interfere with the TGF-b
pathway. sFlt-1 and sEng are thought to act synergistically
in the development of the maternal complications of pre-
eclampsia.59 However, both sFlt-1 and sEng are also present
in amniotic ﬂuid and may thereby aﬀect the developing
fetus. Indeed, elevated levels of sEng in amniotic ﬂuid
during preterm labor were associated with development of
BPD in the infants.63 In contrast, amniotic sFlt-1 levels
during mid-term gestation in humans were not predictive
for the development of pulmonary vascular disease in their
infants,62 although it has recently been shown that elevated
levels of intra-amniotic sFlt-1 lead to reduced VEGF signal-
ing in the developing rat lung, resulting in impaired pulmon-
ary vascular growth and alveolarization in newborn
rat-pups.61 Altogether, this suggests that prenatal exposure
to high sEng and sFlt-1 levels may compromise normal fetal
lung development and may be responsible for the increased
risk of pulmonary vascular disease in preterm born neonates
of pre-eclamptic mothers.14,61
High altitude
It is well-known that living at high altitudes poses a major
challenge to the human body. In adults, residing at high
altitudes can cause altitude-speciﬁc disorders, such as
acute and chronic mountain sickness, high-altitude pulmon-
ary edema, and symptomatic high-altitude pulmonary
hypertension. These conditions can be considered a direct
result of exposure to hypobaric hypoxia.64,65
In pregnant high-altitude residents, maternal exposure to
hypoxia can negatively inﬂuence the oxygen delivery to the
fetus and thereby hamper the development of the fetus. For
example, it has been shown that pre-eclampsia is more
common at high altitudes than at low altitudes. Also, hyp-
oxia is a key factor responsible for lower birth weights and
IUGR in newborns at high altitudes, independently of the
presence of pre-eclampsia.64,66,67 This may, at least in part,
be due to altered function of the placenta due to hypoxia.
Indeed, it has been shown that HIF-1 expression is increased
in placentas from high-altitude residents and that these pla-
centas contain more TGF-b3 as well as VEGF and sFlt-
1,68,69 which may spillover into the fetal circulation and
may impact on the developing pulmonary vasculature.
Because oxygen plays a crucial role in the perinatal
period, the perinatal cardiopulmonary transition proceeds
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more slowly in babies that are born under conditions of
high-altitude hypoxia. It has been shown that such infants
have lower arterial oxygen saturations and that the physio-
logically rapid fall in pulmonary artery pressure after birth
does not occur. This can ultimately lead in adult life to
symptomatic high-altitude pulmonary hypertension, which
is the condition of pulmonary hypertension accompanied by
muscularization of the pulmonary arteries due to hypoxic
vasoconstriction and vascular remodeling. In terminal
stages of the disease, this results in right heart failure.70,71
Another sign of disrupted perinatal transition in these
infants is the persistence of the fetal vascular connections
(ductus arteriosus and foramen ovale).71
An important observation is that the incidence of BPD is
also increased at higher altitudes, the mechanism of which is
currently unknown. It has been hypothesized that the expos-
ure of the preterm infant to the hypoxic environment causes
injury to the lung in a critical stage of development.
Moreover, IUGR can play a role in the higher risk of
BPD as well.72
In summary, although it is well-established that neonatal
pulmonary vascular disease is more common in high-alti-
tude pregnancies, the eﬀect of high-altitude residence
during gestation on the prenatal pulmonary vascular devel-
opment and the exact underlying molecular and/or bio-
chemical mechanisms are still incompletely understood in
humans. Animals studies, however, have implicated a
higher vasoconstrictor reactivity of the pulmonary small
arteries.73–75
Postnatal adverse stimuli
Hyperoxia
The development and maturation of the fetal organs nor-
mally takes place under hypoxic conditions in the uterus.
Preterm birth leads to premature transition of the pulmon-
ary circulation from the hypoxic fetal environment to a rela-
tive hyperoxic postnatal environment (air). For adequate
functioning of the body’s tissues and organs, in particular
the brain, intestines, and kidneys, suﬃcient oxygenation of
these tissues is required. Although the optimal systemic
oxygen saturation in preterm infants is currently unknown,
the consensus is that systemically circulating oxygen satur-
ation levels need to be targeted above 85% to fulﬁll the
oxygen demands of the body. Because of the incomplete
lung development in these infants, with simpliﬁed alveolar
structure and thick alveolar septae, oxygen diﬀusion is ham-
pered. To compensate for these diﬀusion abnormalities,
often high levels of supplemental oxygen are required to
increase alveolar oxygen tension and the diﬀusion gradient
in order to achieve the targeted intravascular oxygen satur-
ation levels. This high level of oxygen supplementation fur-
ther augments the already existing (relative) hyperoxic state
postnatally. The rapid alteration in oxygen concentration at
birth results in changes in oxygen sensitive molecular
mechanisms.3,41,76,77 Under normoxic and/or hyperoxic con-
ditions rapid proteasomal degradation of the HIF-1a sub-
unit occurs and thus binding to the promotor regions of
target genes is hampered.16–18,41 This leads to impaired
VEGF expression, resulting in disrupted angiogenesis and
alveolarization. So, (relative) hyperoxia induces vascular
arrest, leading to pulmonary vascular diseases.
Relative hyperoxia also increases generation of ROS and
induces oxidative stress, an important contributor to the
development of neonatal pulmonary vascular disease. As
outlined above, preterm infants are more prone to oxidative
injury, due to lower levels of antioxidants including vitamin
E, transferrin, and superoxide dismutase, and higher levels
of free iron leading to the production of hydroxyl
radical.28,29,39,78,79
Mechanical ventilation
Mechanical ventilation is essential and life-saving in the
treatment of severely premature infants. Yet mechanical
ventilation can also provoke ventilator-induced lung
injury (VILI). The main mechanism resulting in VILI is
over-distension of the lung, thereby over-stretching of the
distal epithelium and capillary endothelium, which
increases microvascular permeability, inhibits surfactant
production and leads to the release of cytokines into the
alveolar space and the systemic circulation.3,80–83 The type
and duration of mechanical ventilation as well as the
volume and pressure that is used are contributing factors
to the development of VILI.81 Furthermore, the develop-
mental stage of the lung, and thus gestational age at birth,
is an important determinant of VILI. The lung in the
alveolar stage can expand extensively without any
stretch injury, while the more immature saccular lung has
less surface area to expand and is more injury prone to
stretch.83
Mechanical ventilation does not only directly injure the
neonatal lung through overdistension, it also results in alter-
ations in angiogenesis-related factors. Thus, VEGF-1 and its
receptor ﬂt-1 as well as angiopoietin 1 and its receptor Tie2
are downregulated while the TGF-b co-receptor endoglin is
upregulated, in lungs of infants that were mechanically ven-
tilated.84,85 The imbalance in angiogenic factors likely con-
tributed to dysmorphic angiogenesis and altered
alveolarization observed in mechanically ventilated
lungs.84,85
Hypoxia
In addition to periods of hyperoxia, due to premature peri-
natal transition (relative hyperoxia) and the need of supple-
mental oxygen, premature babies are exposed to chronic or
intermittent hypoxia. Hypoxia can be caused by diﬀerent
mechanisms. Often, hypoxia is the result of immature
lungs or occurs in the setting of apnea of prematurity. It
can also be caused by inadequate ventilation of the preterm
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infant.41,77 In infants born extremely premature, studies sug-
gest the persistence of intrapulmonary arteriovenous shunts,
which are physiologically present in the fetus and normally
regress in the early neonatal phase. Beside the immaturity of
the lung in premature born babies, a high pulmonary vas-
cular resistance can also prevent the regression of intrapul-
monary arteriovenous shunts. These shunts bypass the
alveolar capillary gas exchange units and therefore cause
hypoxemia in the neonate.14,86,87
In contrast to the vessels of the systemic circulation that
dilate in response to hypoxia, the pulmonary vasculature
constricts. This so called hypoxic pulmonary vasoconstric-
tion (HPV) is an important physiologic mechanism to
ensure ventilation-perfusion matching by preventing blood
ﬂow to areas of the lung that are not well-ventilated, thereby
optimizing systemic oxygenation. The exact mechanisms
underlying HPV remain incompletely understood, but
animal studies show a critical role of ROS in HPV.88–91
The ‘‘redox theory’’ states that precapillary pulmonary
arterial smooth muscle (PASM) cells are the oxygen-sensing
cells as well as the eﬀector cells.91–95 Mitochondria in the
PASM cells senses a drop in alveolar O2 and respond by
creating a signal that alters opening of redox-sensitive potas-
sium and calcium channels, thereby increasing vascular
tone.91–95 However, it is not yet resolved if increased or
reduced levels of ROS during hypoxia underlie the signal
transduction of HPV.92–95 During general hypoxia, as seen
in premature infants, generalized pulmonary vasoconstric-
tion occurs, which results in an increase in pulmonary vas-
cular resistance and hence pulmonary hypertension. When
sustained, hypoxic vasoconstriction produces vascular
remodeling of the pulmonary vascular bed and, ultimately,
leads to right heart failure.92,93
Besides hypoxic vasoconstriction, it is well-known from
animal studies that hypoxia interferes with the physiological
process of alveolarization. In healthy newborns, a large part
of this process takes place after birth in a normoxic envir-
onment (ambient air, 21% oxygen).2,5,6 Postnatal exposure
to hypoxia has been shown to impair alveolarization, result-
ing in alveolar simpliﬁcation with fewer and larger alveoli.
Since the airway and vascular development and maturation
are closely related, impaired alveolarization also impairs the
vascular maturation in the alveolar wall. Both perturbed
signaling of HIF-1a, VEGF, as well as TGF-b, mediate
these disruptions.41,77,96
Inflammation
Postnatal exposure to intermittent hypoxia and hyperoxia
induces oxidative stress, which—in premature infants—is
insuﬃciently reduced due to immature anti-oxidant mech-
anisms. As a result of direct cellular injury, oxidation of
DNA, induction of cytokines, and recruitment of neutro-
phils and macrophages to the lung, oxidative stress induces
pulmonary inﬂammation. In addition to oxygen-free rad-
icals, mechanical ventilation also triggers pulmonary
inﬂammation. Vice versa, oxygen radicals are rapidly
released by immune cells with the oxidative burst, a crucial
reaction in the immune system.42 Inﬁltration of inﬂamma-
tory cells in the immature lung, and the release of ROS,
results in endothelial and epithelial cell injury.
Interestingly, the pro-inﬂammatory cytokine IL-8 is
increased and the anti-inﬂammatory cytokine IL-10 is
decreased in serum of preterm infants that subsequently
developed BPD,97–99 suggesting that indeed a balance
between pro-inﬂammatory and anti-inﬂammatory cytokines
is required for normal lung development. The exact role of
oxygen tension in perinatal inﬂammation is currently
unknown and should be the topic of future
investigation.41,100–102
Consequences
Short-term consequences
Both premature birth—with incomplete vascular growth,
immature vascular function, and decreased host defenses—
as well as exposure to injurious stimuli after birth, contrib-
ute to an abnormal development of the lung circulation.
Failure of normal lung development will lead to neonatal
pulmonary vascular disease due to an altered function of the
pulmonary vessels (with an increased vasomotor tone), as
well as an altered structure of the pulmonary vasculature,
i.e. vascular remodeling (including smooth muscle cell
proliferation).10,41,103,104
Both these functional and structural changes elevate pul-
monary vascular resistance by narrowing vessel diameter
and by decreasing vascular compliance, leading to pulmon-
ary hypertension.10,14,41,103–106 Furthermore, disruption of
normal pulmonary vascular development leads to an arrest
in the development of the airways. BPD, a common com-
plication of preterm birth, is recognized as a consequence of
disrupted lung development. It is characterized by an arrest
in vascular and alveolar growth, which leads to decreased
and enlarged alveoli and a decrease in number of capillaries
as compared to a normal lung.15,107–110 Besides morbidity
and mortality in the neonatal period, BPD is associated with
a variety of long-term health problems including reduced
lung function, cognitive impairments, cardiovascular dys-
function, and exercise intolerance.111
Long-term consequences
The ‘‘developmental origins of health and disease’’
(DOHaD) concept112 has gained a great deal of attention
in recent years, especially in pediatrics because of the dra-
matically increased survival of premature babies. Since
approximately 10% of births are preterm, a growing
cohort of prematurely born survivors reaches adoles-
cence.113–115 While the majority of research in this ﬁeld
has focused on the developmental origins of metabolic dis-
ease, now there is growing evidence that disruption of
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normal pulmonary vascular development in the perinatal
period contributes to the development of (pulmonary) vas-
cular disease in adulthood. In the late 1990s, it was already
shown that a transient perinatal insult to the pulmonary
circulation increases the risk of developing pulmonary
hypertension.116 It has also been shown that pulmonary
artery pressure is elevated in oﬀspring of mothers with
pre-eclampsia, demonstrating that placental hypoxia
causes pulmonary vascular dysfunction.117 Underlying
mechanisms of this so-called ‘‘fetal or perinatal program-
ming’’ are currently unknown, although oxidative stress
has been proposed to play a key role. As described above,
many perinatal insults are associated with oxidative injury.
Reactive molecules can cause epigenetic changes by inducing
DNA methylation and histone modiﬁcation. Modulation of
epigenetic modiﬁcations during this sensitive developmental
period will alter organogenesis and organ function, thereby
producing long-term programmed consequences.118–121 In
view of the growing awareness of the long-term conse-
quences of neonatal pulmonary vascular disease, it will
become clinically more important to routinely screen high-
risk (ex-premature) patients.
An important diagnostic tool in this patient population is
exercise testing. By placing the cardiopulmonary system
under stress with exercise testing, subtle dynamic abnorm-
alities that are not apparent during conventional static tests
may be revealed. Studies evaluating exercise capacity in
long-term survivors of prematurity have reported highly
variable results, with some research groups reporting no evi-
dence of exercise limitation,122–127 while other investigators
demonstrated signiﬁcantly impaired exercise performance in
former preterms.128–138
Exercise capacity is a resultant of pulmonary function
and cardiovascular performance.139,140 Until now, most stu-
dies concerning long-term health outcomes of (extremely)
premature infants have focused on respiratory outcomes.
Indeed it is well-known that pulmonary function in child-
hood and adolescence is impaired in these patients, and this
is even more pronounced in survivors of neonatal pulmon-
ary vascular diseases like BPD.110,113,141–144
Less is known about cardiovascular function in sur-
vivors of neonatal pulmonary vascular disease. Exposure
of the immature pulmonary vasculature to injurious stimuli
after birth can potentially result in remodeling of the pul-
monary vascular bed, in endothelial dysfunction, pulmon-
ary hypertension, and, ﬁnally, right ventricular failure. A
recent cardiac magnetic resonance imaging (MRI) study
demonstrated that young adults, born preterm, have smal-
ler right ventricular lumen size and greater mass, resulting
in right ventricular dysfunction.145 Although less pro-
nounced, adverse changes have also been shown in the
left ventricle.146 These alteration in cardiac function and
structure may increase the risk for cardiovascular events
later in life, thereby contributing disproportionately to
the burden of adult cardiovascular disease in the
future.115,141,145,146
Clinical implications
Oxygen therapy is a cornerstone in the treatment of prema-
ture infants and is crucial for their survival. However, as
outlined above, too much oxygen, or hyperoxia, causes
injury and damage to several tissues including the lung.
Paradoxically, hypoxia also interrupts normal lung vascular
development. Therefore, both hyperoxia and hypoxia,
together or independently, can lead to pulmonary vascular
disease. Consequently, there is uncertainty about the opti-
mal target of oxygen saturation in (prematurely born) neo-
nates. A recently published systematic review and
meta-analysis concluded that infants (born <28 weeks of
gestation) cared for with a liberal saturation target (SpO2
91–95%) had signiﬁcantly lower mortality before hospital
discharge than infants cared for with a restricted oxygen
target (SpO2 85–89%), although the quality of evidence
for this estimate of eﬀect was low. No signiﬁcant diﬀerence
was found for the incidence of BPD.147–149
In view of the growing cohort of adult survivors of pre-
maturity and/or neonatal vascular disease, more research
into the long-term consequences of perinatal pulmonary
vascular events is imperative. Since this is a relatively new
patient population, there is a lack of consensus for the
follow-up of high-risk (formerly premature) patients. The
American Heart Association and American Thoracic
Society have made a guideline for diagnosis, evaluation,
and monitoring of pediatric patients with pulmonary hyper-
tension.150 They recommend monitoring of children with
pulmonary hypertension (or neonatal pulmonary vascular
disease) provided by comprehensive, multidisciplinary
team of pulmonologists, cardiologists, neonatologists, anes-
thesiologists, and experienced nurses. Children with chronic
diﬀuse lung disease should be evaluated for concomitant
cardiovascular disease or pulmonary hypertension by echo-
cardiogram every 3–6 months. The 6-min walk distance
(6MWD) test or cardiopulmonary exercise test (CPET)
can be useful to monitor exercise tolerance. MRI can be
performed to assess right ventricular function and struc-
ture.150 These diagnostic tools could be very useful in the
development of a follow-up program that might facilitate an
optimal transition of the patient from the pediatric to the
adult setting to ensure strong continuity of care to optimize
clinical outcome. It is a future challenge to evolve a follow-
up program for (neonatal) pulmonary vascular disease that
ensures early detection of health problems in these patients,
thereby diminishing the cardiovascular morbidity and mor-
tality and improving the quality of life. Furthermore, the
development of an exercise training program tailored for
prematurely born adolescents, who may be at higher risk
for early-onset adult diseases, should be considered.
Increasing the level of regular physical activity has beneﬁcial
eﬀects on overall health and plays an important role in the
prevention of diseases in the long term. Establishing
early, adequate levels of ﬁtness and activity should therefore
be a cornerstone in the follow-up of formerly premature
adults.
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Conclusions
Both antenatal and postnatal injurious stimuli can disrupt
the normal lung vascular development, potentially leading
to neonatal pulmonary vascular diseases entities such as
BPD and pulmonary hypertension. These diseases not
only contribute to morbidity and mortality in the neonatal
period, but have also been shown to signiﬁcantly increase
the risk for a variety of health problems later in life.
Pulmonary vascular disease can lead to endothelial dysfunc-
tion, vascular remodeling, and ultimately to cardiac dys-
function (right ventricular hypertrophy and failure).
Oxygen tension is a key player in the pathogenesis of
neonatal pulmonary vascular diseases. Both antenatal and
postnatal exposure to either hypoxia and/or hyperoxia con-
tribute to disruption of the normal development of the pul-
monary vascular bed (Fig. 3). Despite decades of research
focusing on the role of oxygen in pulmonary vascular devel-
opment, the exact pathophysiologic mechanisms remain
incompletely understood. Furthermore, it is important to
study the optimal targeted oxygen saturation limits in
much more detail, in order to improve clinical practice at
the neonatal intensive care unit. Future endeavors should
also include the development of a follow-up program tai-
lored towards prematurely born adolescent survivors and/or
survivors of (transient) neonatal pulmonary vascular dis-
eases. Such a program may prove a key step in the early
diagnosis and treatment of long-term vascular diseases to
reduce morbidity and mortality in adult life, which is neces-
sary in order to improve the health of the growing cohort of
prematurely born survivors of neonatal pulmonary vascular
disease and to reduce the burden of adult cardiopulmonary
morbidity and mortality.
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